Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Open accessThe DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index; 78 of the 118 sources its claims cite were checked for support.
Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have emerged as promising therapeutic agents with potent anti-inflammatory properties and diverse clinical implications. This in-depth review article explores the mechanisms behind the anti-inflammatory actions of GLP-1RAs and assesses their prospective applicability in a wide range of disease scenarios. The current review establishes the significance of comprehending the anti-inflammatory role of GLP-1RAs and identifies pertinent research gaps. A concise overview of inflammation and its clinical consequences underscores the critical need for effective anti-inflammatory interventions. Subsequently, the article elucidates the intricate mechanisms through which GLP-1RAs modulate immune cell signaling and regulate the nuclear factor-kappa B (NF-κB) pathway. Detailed discussions encompass their impact on inflammatory responses, cytokine production, and attenuation of oxidative stress. The exposition is substantiated by a collection of pertinent examples and an extensive array of references from both preclinical and clinical investigations. The historical trajectory of GLP-1RA drugs, including exenatide, lixisenatide, liraglutide, and semaglutide, is traced to delineate their development as therapeutic agents. Moreover, the review emphasizes the therapeutic potential of GLP-1RAs in specific disease contexts like type 2 diabetes, a neurodegenerative disorder, and inflammatory bowel disease (IBD), shedding light on their anti-inflammatory effects through rigorous examination of preclinical and clinical studies. The article also provides an outlook on future perspectives for GLP-1RAs, encompassing the domains of diabetes, neurodegenerative diseases, and IBD. In conclusion, GLP-1RAs exhibit substantial anti-inflammatory effects, rendering them promising therapeutic agents with broad clinical implications. They are very useful in a wide variety of diseases because they regulate immunological responses, block NF-κB activation, and decrease production of pro-inflammatory cytokines. Ongoing research endeavors aim to optimize their therapeutic use, delineate patient-specific treatment paradigms, and explore novel therapeutic applications. GLP-1RAs represent a significant breakthrough in anti-inflammatory therapy, offering novel treatment options, and improved patient outcomes.
Overview
CoChat Summary
TL;DR
This review argues that GLP-1 receptor agonists (GLP-1RAs) have anti-inflammatory effects beyond glucose lowering, acting through immune-cell signaling, NF-κB suppression, oxidative stress reduction, and related pathways. It concludes that these drugs show promise across type 2 diabetes, neurodegenerative disease, and inflammatory bowel disease, but emphasizes that more long-term and disease-specific evidence is needed.
Key findings
- The review identifies several anti-inflammatory mechanisms for GLP-1RAs: suppression of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β; increased IL-10; inhibition of NF-κB; activation of AMPK; and reduction of reactive oxygen species.
- In diabetes-related studies, liraglutide and semaglutide improved glycemic outcomes and were also linked to inflammation reductions; for example, liraglutide reduced the mean CRP concentration in a retrospective study of obese individuals with T2DM, and semaglutide significantly reduced hs-CRP in people with T2D and cardiovascular disease.
- In obesity/weight-loss trials cited in the review, liraglutide 3.0 mg in the SCALE study produced dose-responsive weight loss of 6.0 to 8.8 kg, versus 0.2 to 3.0 kg with placebo; in another trial, exenatide plus lifestyle change led to −6.2 ± 0.5 kg versus −4.0 ± 0.5 kg with lifestyle plus placebo.
- For neurodegenerative disease, the review cites a preliminary clinical trial in Parkinson’s disease where exenatide improved patients by 2.7 points on the MDS-UPDRS after 12 months, compared with a 2.2-point decline in controls, and a pilot study in 45 individuals with mild PD using single-blind design.
Methods
- Narrative review of preclinical and clinical literature on GLP-1RAs and inflammation, with disease-focused discussion spanning diabetes, neurodegenerative disorders, and inflammatory bowel disease.
- The paper synthesizes examples from animal models, cell studies, retrospective studies, and clinical trials; specific cited studies include obese individuals with T2DM, AD and PD patients, and IBD models/patients.
- Main analysis is qualitative/mechanistic: the review organizes evidence by pathways and disease contexts rather than performing a meta-analysis or pooled quantitative synthesis.
Limitations
- The paper states that there is limited long-term data on the anti-inflammatory effects of GLP-1RAs across diseases and that these drugs have not yet been tested for long-term effectiveness and safety in terms of inflammation.
- It also states that further studies are necessary to determine optimal dosage schedules, treatment periods, and the best combinations with other therapies.
- Evident from the text: this is a review rather than an original study, so its conclusions depend on the quality and heterogeneity of the cited studies; the paper itself notes that responses may vary by disease severity, comorbidities, and patient characteristics.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
65 Valid · 10 Not valid · 35 Not checked · 26 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Restoring NF-κB activity reversed cytokine-induced reductions in eNOS (NOS3) mRNA levels.”
§ Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications > Regulation of nuclear factor-kappa B pathway
What the sources say
- Disputedcites [41] Hattori Y Jojima T Tomizawa A, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010; 53: 2256– 2263. 20593161 sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports that inhibiting NF-κB partially prevented the TNFα-induced reduction in eNOS mRNA. It also reports that liraglutide attenuated that reduction; the paper says suppression, not restoration, of NF-κB activity accompanied this effect. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Recorded clinical data in 2019 demonstrated that liraglutide, a specific GLP-1RA, effectively diminishes adiposity and overall body fat by enhancing lipolysis among patients with T2DM who are obese. 76”
§ Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications > Impact of GLP1-RAs on diabetes and inflammation
What the sources say
- Disputedcites [76] Anholm C Kumarathurai P Samkani A, et al. Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: a randomized trial. Diabetes Obes Metab 2019; 21: 2012– 2016. 31050161 sourceExperimental — accuracy not yet measured
The Lipolysis results report that liraglutide reduced, rather than enhanced, estimated lipolysis compared with placebo. The paper reports weight loss, but does not establish a reduction in overall body fat or attribute weight loss to enhanced lipolysis. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The nuclei containing GLP1-R are located in the circumventricular area postrema and median eminence, as well as in the nucleus of the solitary tract (NTS). 98”
§ Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications > GLP-1RA and the inflammatory link to ND
What the sources say
- Disputedcites [98] Gabery S Salinas CG Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 2020; 5: 1– 18. PMC7213778 32213703 sourceExperimental — accuracy not yet measured
The section on GLP-1R-expressing neurons in the ARH and AP reports GLP-1R-positive cells in the area postrema but explicitly says there were no GLP-1R-positive cell bodies in the NTS. Figure 4 describes only limited GLP-1R staining in tanycytes lining the median eminence, not GLP-1R-containing nuclei there. No page number was available in our copy. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“There was a dose-response relationship between liraglutide and increased nitric oxide generation in.”
§ Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications > Regulation of nuclear factor-kappa B pathway
What the sources say
- Supportedcites [41] Hattori Y Jojima T Tomizawa A, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010; 53: 2256– 2263. 20593161 source
The Results section reports that liraglutide increased nitric oxide in HUVECs in a concentration-dependent manner. This directly supports the attributed dose-response relationship. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, are suppressed by GLP-1R in immune cells.”
§ Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications > Mechanisms of action
What the sources say
- Partly supportedcites [33] Pang J Feng JN Ling W, et al. The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs – therapeutic potential exploration in lung injury. Acta Pharm Sin B 2022; 12: 4040– 4055. 36386481 PMC9643154 sourceExperimental — accuracy not yet measured
The anti-inflammation section (page not provided) reports that in vivo exenatide treatment suppressed TNF-α, IL-1β and IL-6 in peripheral blood mononuclear cells. It does not establish that GLP-1R in those immune cells caused the suppression: the same section says GLP-1R was not detected in the tested human immune cells and that receptor mediation remains undetermined. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [36] Ferreira ST. Brain insulin, insulin-like growth factor 1 and glucagon-like peptide 1 signalling in Alzheimer’s disease. J Neuroendocrinol 2021; 33: 1– 11. 33739563 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
75 more claims · 38 with their cited sources checked
Create a free account to see all 136 claims and every source verdict.
- It may state two separate claims as one. 47
- Probably not a substantial claim. 13
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Specifically, moro anthocyanins activate AMPK, enhance lipolysis, and suppress adipogenesis, reducing fat accumulation in experimental models [348,349].”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [348]
In the citing paper
“Although direct studies evaluating moro extract with GLP-1RAs are lacking, current evidence supports its inclusion in a multi-targeted obesity regimen [120,348].”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [348]
In the citing paper
“the suppression of pro-inflammatory cytokines (e.g., TNF-α, IL-6) and inflammatory pathways, including the blocking of NF-κB activation [39, 91], contributes to the establishment of an anti-inflammatory environment that can mitigate oxidative stress and inflammation induced muscle protein catabolism, thereby supporting the preservation of SMM and functional capacity [40].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications > Modulation of lipid metabolism pathway
“Subsequent research conducted by Parlevliet et al. 55 substantiates this point while also revealing both DPP-1i (exendin-4) and GLP1-RA result in decreased hepatic lipogenesis among mice consuming high-fat diets.”
§ Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications > Impact of GLP1-RAs on diabetes and inflammation
“Exendin-4, a GLP-1 analog, showed cardioprotective properties in a diabetic animal model by preventing heart remodeling and diastolic dysfunction.”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“10.1007/s00125-010-1831-8”
Cited work 10.1007/s00125-010-1831-8 · retracted 2011-12-15 · notice 10.1007/s00125-011-2394-z · this paper published 2024-01
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
RetractedReactive Oxygen Species in Inflammation and Tissue Injury
Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P., & Malik, A. B. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5149 · Cited by 4,897
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665 · cited 1×
“51 Upon direct infusion of carbohydrates or fats into the ileum, healthy human bodies witness a swift rise in GLP-1 plasma concentrations.”
BackgroundGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555 · cited 1×
“78 Recent rigorous scientific studies, specifically randomized controlled trials, have proven that GLP-1RAs consistently offer substantial weight loss advantages beyond the early stages of treat-ment.”
BackgroundInflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235 · cited 1×
“Injured neurons and synapses produce chemicals, and inflammatory regulatory systems are disrupted, all of which contribute to the progression of these ND. 95 There is a lack of knowledge on GLP-1RA’s precise effect on neurogenesis.”
BackgroundDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Mucosal healing in inflammatory bowel diseases: a systematic review
Neurath, M. F., & Travis, S. P. L. (2012) · Gut · doi:10.1136/gutjnl-2012-302830 · Cited by 810
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · cited 2×
“98 The transportation of GLP-1 or its ligands through the central nervous system (CNS) may be mediated by astrocytes and tanycytes.”
Background
Research works printed but not linked: 2
- Yang F, 2021, Front Pharmacol, 12, 1
- Lee Y-S, 2016, Mediators Inflamm, 11, 1
Cited by
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H., Peters, T. M., & Eisenberg, M. J. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.01.021 · Cited by 241
Oxidative Stress: A Culprit in the Progression of Diabetic Kidney Disease
Wang, N., & Zhang, C. (2024) · Antioxidants · doi:10.3390/antiox13040455 · Cited by 218
Wang, W., Wang, Q., Qi, X., Gurney, M., Perry, G., Volkow, N. D., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14313 · Cited by 180
Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review
Badulescu, S., Tabassum, A., Le, G. H., Wong, S., Phan, L., Gill, H., Llach, C.-D., McIntyre, R. S., Rosenblat, J., & Mansur, R. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114622 · Cited by 90
“GLP1-RAs have been associated with the modulation of dopaminergic neurotransmission, one of the key molecular mediators of reward processes [25], either directly or indirectly via enhancement of insulin sensitivity and inhibition of pro-inflammatory cytokines [26 – 30].”
BackgroundKarakasis, P., Theofilis, P., Vlachakis, P. K., Korantzopoulos, P. G., Patoulias, D., Antoniadis, A. P., & Fragakis, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010209 · Cited by 112
Metadata
- Authors
- Alharbi, S. H.
- Affiliations
- Imam Mohammad ibn Saud Islamic University (SA)
- Corresponding author
- Alharbi, Saleh Hadi
- ORCID
- Alharbi, Saleh Hadi
- Venue
- Therapeutic Advances in Endocrinology and Metabolism
- Publisher
- SAGE Publications
- Published
- 2024-01
- Volume
- 15
- Pages
- 20420188231222367-20420188231222367
- ISSN
- 2042-0188 (ISSN-L)
- 2042-0196
- PMC
- PMC10823863
- OpenAlex
- W4391294421
- Cited by
- 358
- References
- 116
- Citations by year
- 2026: 169 · 2025: 147 · 2024: 42
- FWCI
- 20.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutic Advances in Endocrinology and Metabolism (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- GLP-1 receptor agonists, anti-inflammatory activity, NF-κB signaling, inflammatory cytokines, oxidative stress, exenatide, lixisenatide, liraglutide, semaglutide, type 2 diabetes, neurodegenerative diseases, inflammatory bowel disease, immune cell signaling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. https://app.cochat.ai/papers/10.1177/20420188231222367
- The paper
- Alharbi, S. H. (2024). Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Therapeutic Advances in Endocrinology and Metabolism. https://doi.org/10.1177/20420188231222367
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.